|
Daehan Nupharm Launches World’s First Fluconazole Formulation for Dogs, ‘DH Fuzole Tab.’
2024.06.04
|
|---|
|
Daehan Nupharm has announced the launch of two new veterinary medicines under its exclusive animal hospital brand, DiAange
DH Fuzole Tab. is an antifungal treatment for Malassezia dermatitis, one of the most common dermatological conditions in companion dogs. Skin disorders account for a significant portion of veterinary consultations, and antifungal agents make up a large share of prescribed medications in this field. While human antifungal drugs such as itraconazole, fluconazole, and terbinafine are widely used, there has been a lack of verified animal-specific antifungal formulations, leading veterinarians to rely on human medicines. To address this unmet need, Daehan Nupharm has been actively developing veterinary antifungal products to provide veterinarians with more tailored treatment options. Following the 2023 launch of Teramin Tab. (terbinafine) and several years of development since 2019 based on the human formulation Fuzole Tab., the company has now achieved a global milestone, securing regulatory approval for the world’s first fluconazole formulation for dogs. The newly introduced PROCOX Tab., formulated with firocoxib, offers fast and potent pain relief with high COX-2ivity and minimal COX-1 inhibition. Thisive action reduces the risk of gastrointestinal side effects commonly associated with non-selective NSAIDs. As companion dogs live longer and chronic conditions become more prevalent, the market for veterinary NSAIDs (e.g., meloxicam, carprofen, firocoxib) continues to expand annually. Currently, the domestic market relies heavily on imported products from global pharmaceutical companies. The launch of PROCOX Tab. is expected to enhance treatment accessibility and cost efficiency through local manufacturing while broadening therapeutic options for veterinarians. Daehan Nupharm is committed to transitioning human drugs into veterinary formulations to ensure safer and more effective treatments for animals. The company plans to obtain regulatory approval for three additional veterinary products and file an IND (Investigational New Drug) application for one new compound within this year.
|


Home
